Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Pazopanib Exposure in RCC Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* signature of informed consent~* age ≥ 18 years~* histologically confirmed renal cell carcinoma with clear cell component and either locally progressed or metastasized~* ECOG ≤ 2~* No previous systemic therapy for locally progressed or metastasized renal cell carcinoma (previous adjuvant or neo-adjuvant therapy is permitted)~* Adequate organ function~* Female patients with child-bearing potential with negative serum pregnancy test within 2 weeks prior to first dose of study medication and adequate contraception~* Lactating females~Exclusion Criteria:~* Clinically suspected and known metastases of the central nervous system or carcinomatous meningitis except in asymptomatic patients with previously treated CNS-metastases and no necessity of steroids or anti-epileptic medication ≥ 6 months prior to start of the study medication~* Clinically significant gastrointestinal conditions with risk of increase of gastrointestinal bleeding due to (but not limited to)~* active peptic ulceration~* known intraluminal metastases with risk of bleeding~* chronic-inflammatory intestinal disease (like Morbus Crohn, ulcerative colitis) or another gastrointestinal disease with increased risk of perforation~* abdominal fistulas in anamnesis~* Clinically significant gastrointestinal conditions which can influence absorption of the IMP, among others (but not limited to)~* malabsorption syndrome~* resection of stomach or small bowel~* Current uncontrolled infection~* QTc corrected for heart frequency according to the Bazett formula~* One or more of the following cardiovascular diseases within the last 6 months in the anamnesis:~* cardiac angioplasty or coronary stent implantation~* myocardial infarction~* instable angina pectoris~* coronary-arterial bypass surgery~* symptomatic peripheral arterial occlusive disease~* Heart failure NYHA III or IV~* Poorly controlled high blood pressure~* Cerebrovascular disease, including transitory ischemic attacks, pulmonary artery embolism or untreated deep vein thrombosis within 6 months of study inclusion~* Previous major surgery or traumas within 28 days prior to start if study treatment or non-healing wound, fracture or ulcer~* Clinical signs of active bleeding or bleeding diathesis~* Known endobronchial lesions or lesions infiltrating the large lung arteries~* Haemoptyses of \> 2.5 mL within 8 weeks prior to first intake of study medication~* Any other severe and/or instable medical or psychiatric pre-existing or other condition influencing patient safety, consent capacity or compliance within the study~* Incapacity or rejection to stop not allowed medication prior to first intake of study drug and pause for the duration of the trial~* Treatment with one of the following anti-tumour therapies:~* Radiation or tumour embolism within 14 days before first intake of study drug~* Chemotherapy, Immunotherapy, biological therapy, study medication or hormonal therapy within 14 days or 5 half-lives of the respective substance (whichever is longer) before first intake of the study drug. Neo-adjuvant or adjuvant therapy must have been completed for at least 6 months.~* Any present toxicity \> CTC 1° from prior anti-tumour therapy and/or toxicities worsening in severity except alopecia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal plasma level patients and low plasma level patients. (Type: EXPERIMENTAL): 1. Patients with normal Pazopanib plasma trough levels; normal plasma level patients (NPLP).~2. Patients with low Pazopanib plasma trough levels, low plasma level patients (LPLP).

Based on this trial design, predict the completion outcome and termination type (if applicable).